|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 28984 |
FusionGeneSummary for PRRC2C_FASLG |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: PRRC2C_FASLG | Fusion gene ID: 28984 | Hgene | Tgene | Gene symbol | PRRC2C | FASLG | Gene ID | 23215 | 356 |
| Gene name | proline rich coiled-coil 2C | Fas ligand | |
| Synonyms | BAT2-iso|BAT2D1|BAT2L2|XTP2 | ALPS1B|APT1LG1|APTL|CD178|CD95-L|CD95L|FASL|TNFSF6|TNLG1A | |
| Cytomap | 1q24.3 | 1q24.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | protein PRRC2CBAT2 domain containing 1BAT2 domain-containing protein 1HBV X-transactivated gene 2 proteinHBV XAg-transactivated protein 2HBxAg transactivated protein 2HLA-B-associated transcript 2-like 2proline-rich and coiled-coil-containing prote | tumor necrosis factor ligand superfamily member 6CD95 ligandFas ligand (TNF superfamily, member 6)apoptosis (APO-1) antigen ligand 1apoptosis antigen ligandfas antigen ligandmutant tumor necrosis factor family member 6tumor necrosis factor ligand 1 | |
| Modification date | 20180523 | 20180522 | |
| UniProtAcc | Q9Y520 | P48023 | |
| Ensembl transtripts involved in fusion gene | ENST00000426496, ENST00000392078, ENST00000476522, ENST00000367742, ENST00000338920, | ENST00000340030, ENST00000367721, | |
| Fusion gene scores | * DoF score | 12 X 13 X 5=780 | 1 X 1 X 1=1 |
| # samples | 17 | 1 | |
| ** MAII score | log2(17/780*10)=-2.19793937761191 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(1/1*10)=3.32192809488736 | |
| Context | PubMed: PRRC2C [Title/Abstract] AND FASLG [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | FASLG | GO:0000122 | negative regulation of transcription by RNA polymerase II | 17557115 |
| Tgene | FASLG | GO:0008625 | extrinsic apoptotic signaling pathway via death domain receptors | 18835034|26582200 |
| Tgene | FASLG | GO:0016525 | negative regulation of angiogenesis | 18835034 |
| Tgene | FASLG | GO:0043065 | positive regulation of apoptotic process | 14749367|21625644 |
| Tgene | FASLG | GO:0070231 | T cell apoptotic process | 17076679 |
| Tgene | FASLG | GO:0070266 | necroptotic process | 11101870 |
| Tgene | FASLG | GO:0097190 | apoptotic signaling pathway | 11101870 |
| Tgene | FASLG | GO:0097191 | extrinsic apoptotic signaling pathway | 22891283 |
| Tgene | FASLG | GO:0097527 | necroptotic signaling pathway | 11101870 |
| Tgene | FASLG | GO:1903514 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | 26582200 |
| Tgene | FASLG | GO:2000353 | positive regulation of endothelial cell apoptotic process | 18835034 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | BRCA | TCGA-A7-A0CG-01A | PRRC2C | chr1 | 171454874 | + | FASLG | chr1 | 172634762 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5UTR-3UTR | ENST00000426496 | ENST00000340030 | PRRC2C | chr1 | 171454874 | + | FASLG | chr1 | 172634762 | + |
| 5UTR-3UTR | ENST00000426496 | ENST00000367721 | PRRC2C | chr1 | 171454874 | + | FASLG | chr1 | 172634762 | + |
| 5UTR-3UTR | ENST00000392078 | ENST00000340030 | PRRC2C | chr1 | 171454874 | + | FASLG | chr1 | 172634762 | + |
| 5UTR-3UTR | ENST00000392078 | ENST00000367721 | PRRC2C | chr1 | 171454874 | + | FASLG | chr1 | 172634762 | + |
| 3UTR-3UTR | ENST00000476522 | ENST00000340030 | PRRC2C | chr1 | 171454874 | + | FASLG | chr1 | 172634762 | + |
| 3UTR-3UTR | ENST00000476522 | ENST00000367721 | PRRC2C | chr1 | 171454874 | + | FASLG | chr1 | 172634762 | + |
| 5UTR-3UTR | ENST00000367742 | ENST00000340030 | PRRC2C | chr1 | 171454874 | + | FASLG | chr1 | 172634762 | + |
| 5UTR-3UTR | ENST00000367742 | ENST00000367721 | PRRC2C | chr1 | 171454874 | + | FASLG | chr1 | 172634762 | + |
| 5UTR-3UTR | ENST00000338920 | ENST00000340030 | PRRC2C | chr1 | 171454874 | + | FASLG | chr1 | 172634762 | + |
| 5UTR-3UTR | ENST00000338920 | ENST00000367721 | PRRC2C | chr1 | 171454874 | + | FASLG | chr1 | 172634762 | + |
Top |
FusionProtFeatures for PRRC2C_FASLG |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| PRRC2C | FASLG |
| Cytokine that binds to TNFRSF6/FAS, a receptor thattransduces the apoptotic signal into cells (PubMed:26334989,PubMed:9228058). Involved in cytotoxic T-cell-mediated apoptosis,natural killer cell-mediated apoptosis and in T-cell development(PubMed:9228058, PubMed:7528780, PubMed:9427603). Initiatesfratricidal/suicidal activation-induced cell death (AICD) inantigen-activated T-cells contributing to the termination ofimmune responses (By similarity). TNFRSF6/FAS-mediated apoptosishas also a role in the induction of peripheral tolerance (Bysimilarity). Binds to TNFRSF6B/DcR3, a decoy receptor that blocksapoptosis (PubMed:27806260). {ECO:0000250|UniProtKB:P41047,ECO:0000269|PubMed:17557115, ECO:0000269|PubMed:27806260,ECO:0000269|PubMed:7528780, ECO:0000269|PubMed:9228058,ECO:0000269|PubMed:9427603}. Tumor necrosis factor ligand superfamily member 6,soluble form: Induces FAS-mediated activation of NF-kappa-B,initiating non-apoptotic signaling pathways (By similarity). Caninduce apoptosis but does not appear to be essential for thisprocess (PubMed:27806260). {ECO:0000250|UniProtKB:P41047,ECO:0000269|PubMed:27806260}. FasL intracellular domain: Cytoplasmic form induces genetranscription inhibition. {ECO:0000269|PubMed:17557115}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for PRRC2C_FASLG |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for PRRC2C_FASLG |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| PRRC2C | ELAVL1, SIRT7, HINFP, ITGA4, TARDBP, PARK2, LGR4, CSNK2A2, SHFM1, AURKA, AURKB, CEP57, HAUS2, CEP76, LGALS3BP, TP53, QPRT, FBL, RABGGTB, PRMT8, ZFP41, NTRK1, SRPK2, RPL10, C10orf12, FOXK2, ATOH1, JPH4, SNRNP70, CHCHD10, TRPC4AP, SFPQ, CYLD, TRIM25, G3BP1 | FASLG | TNFRSF10B, BID, EZR, FADD, FAS, MAPK8, MSN, CASP10, CASP8, RHOA, ARHGDIA, TNFRSF1A, FNBP1, PACSIN2, GRB2, FN1, MMP7, TNFRSF6B, FYN, LCK, GRAP, GRAP2, NCK1, PTPN13, FGR, LYN, ITSN2, PPIAP11, OSTF1, SNX33, HCK, YES1, SRC, SNX9, SRGAP1, SH3PXD2B, BTK, EPS8L3, ARHGAP9, MYO15A, NCK2, FYB, TEC, SPTA1, SAMSN1, SH3RF2, DLG2, SORBS3, SKAP2, CRK, NCKIPSD, SH3PXD2A, BAIAP2L1, SH3GL3, TJP3, CACNB3, MPP4, PIK3CA, DNMBP, DOCK4, KALRN, MACC1, SRGAP3, MIA, SRGAP2, NCF1, ITK, CACNB4, RIMBP3C, SNX18, CFLAR, TRIP6, RGS20, KRT40, NOTCH2NL, CLPX, P3H4, PRMT2, EIF2AK1, LEPREL2, MOSPD2, PIK3R1 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for PRRC2C_FASLG |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for PRRC2C_FASLG |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | FASLG | C0878544 | Cardiomyopathies | 2 | CTD_human |
| Tgene | FASLG | C0003873 | Rheumatoid Arthritis | 1 | CTD_human |
| Tgene | FASLG | C0004153 | Atherosclerosis | 1 | CTD_human |
| Tgene | FASLG | C0007131 | Non-Small Cell Lung Carcinoma | 1 | CTD_human |
| Tgene | FASLG | C0007193 | Cardiomyopathy, Dilated | 1 | CTD_human |
| Tgene | FASLG | C0007273 | Carotid Artery Diseases | 1 | CTD_human |
| Tgene | FASLG | C0011875 | Diabetic Angiopathies | 1 | CTD_human |
| Tgene | FASLG | C0013182 | Drug Allergy | 1 | CTD_human |
| Tgene | FASLG | C0019158 | Hepatitis | 1 | CTD_human |
| Tgene | FASLG | C0020474 | Hyperlipidemia, Familial Combined | 1 | CTD_human |
| Tgene | FASLG | C0025202 | melanoma | 1 | CTD_human |
| Tgene | FASLG | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Tgene | FASLG | C0039584 | Testicular Diseases | 1 | CTD_human |
| Tgene | FASLG | C0162557 | Liver Failure, Acute | 1 | CTD_human |
| Tgene | FASLG | C0242488 | Acute Lung Injury | 1 | CTD_human |
| Tgene | FASLG | C1328840 | Autoimmune Lymphoproliferative Syndrome | 1 | ORPHANET;UNIPROT |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|